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WHAT THIS PAPER ADDS
This study is the first to assess prevalence of snus awareness, trial, and uptake in a population that has had over three years of exposure 
to snus marketing in a probability-based sample. Using very rigorous measures, we examine reasons for trial, reasons for rejecting 
regular use, and motivations for continued use. We demonstrate the important of experience with conventional smokeless tobacco as a 
predictor of snus uptake.
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Abstract
 Objective—To determine whether snus might become a strategy for reducing the harm 
associated with cigarette smoking in the U.S. as appears to be the case in Sweden, we examined 
receptivity to snus use in two cities with the greatest exposure to the major brands.
 Methods—A dual frame, telephone survey and a brief mail survey were conducted in 2011 
and 2012 in Indianapolis, Indiana and Dallas/Fort Worth Texas. Over 5000 adults completed 
surveys. Trial, ever use, current use, and reasons for using or quitting snus after trial were 
measured.
 Results—Among male smokers, 29.9% had ever tried snus (CI: 22.7–38.1), and 4.2% were 
current users (CI: 1.6–10.7). Among female smokers, 8.5% ever tried snus (CI: 4.4–15.7) and 
current use was unknown. Current use was virtually absent among former and never smokers. A 
major predictor of any level of snus use was current use of conventional smokeless tobacco. Those 
who tried and gave up snus cited curiosity (41.3%) and the fact that it was available at low or no 
cost (30%) as reasons for trial; reasons for not continuing included preferring another form of 
tobacco (75.1%), and disliking the mouth feel (34.6%). Almost all current snus users indicated 
that they were trying to cut down on cigarettes, but few (3.9%) were using it to quit smoking 
entirely.
 Conclusions—The low rate of adoption of snus suggests that neither the hopes nor the fears 
surrounding this new product are likely to b e realized in the United States with the current 
marketing patterns.
The two largest U.S. cigarette makers introduced low nitrosamine smokeless tobacco 
products (LNSLT) into several cities in 2006 and 2007, and by 2010 were marketing snus 
nationally under their major brand names, Camel and Marlboro. 1, 2 Two other cigarette 
companies experimented with but soon dropped out of the snus market. 3 Snus differs from 
most conventional smokeless tobacco (CSLT) in that it a) has lower levels of tobacco 
specific nitrosamines, which are strong lung and oral carcinogens; b) does not require 
spitting; and c) is packaged in small sachets that can be unobtrusively placed under the lip. 
A panel of experts has estimated that using snus is 90% less harmful than smoking 
cigarettes. 4 Most researchers agree that if smokers switched to snus, their health would 
improve. This is based this on the Swedish experience, where the substantial reductions in 
lung and oral cancers have been attributed to the substitution of snus for smoking, 
particularly among males.5, 6 Consequently, promotion of snus for smokers has been 
discussed as a potential tobacco harm reduction strategy.7–11
Promoting snus for harm reduction has been controversial. Some are concerned that 
communicating snus’s lower risk relative to cigarettes will attract former smokers and non-
smokers who would otherwise remain tobacco free.1213, 1415 Also, snus use might reduce 
smoking cessation rates by serving as a temporary source of nicotine when smoking is 
prohibited. Much of the advertising seems to promote dual use with cigarettes 16, 17 which 
might result in extended exposure to combustible tobacco and therefore cause increased 
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morbidity and mortality. Furthermore, some question whether the Swedish experience with 
snus can be generalized to countries where smokeless tobacco has not been adopted with 
equal enthusiasm. 18 Consequently, surveillance of the receptivity to snus and its impact on 
smoking in the U.S., one of the few countries where its sale is permitted, is an important 
component of the empirical work that is needed to bring scientific evidence to bear on this 
controversy.
Several papers estimating snus trial in U.S. test markets have been published. These have 
found that trial is most prevalent among male smokers, 19, 20 particularly those ages 18 to 
24, 29% of whom reported trying snus in the past year. 20 Recently, national estimates of 
both trial and current use have been reported. 21, 22 McMillen, Maduka and Winickoff 
(2012), reported that in 2010, 5.1% of the population (8% of males and 2% of females) had 
tried snus, and that trial among daily and nondaily smokers was 12.9% and 4.1%, 
respectively (or 11.4% of all smokers).1 These investigators estimated that current use (i.e. 
past month use) was less than 1%. King, Dube and Tynan (2012) estimated the prevalence of 
past month use to be 1.4% of the population – higher among men (2.5%) than women 
(0.4%). Their findings imply a substantially higher rate of current snus use among male 
smokers, perhaps approaching 9%. It is likely, however, that this is an overestimate of 
current use because the question used to measure snus use did not clearly distinguish it from 
CSLT. New tobacco products are frequently confused with others unless efforts are made to 
confirm that the product in question is, indeed, one of the novel brands available. 23 Both 
national studies were conducted very early (6–18 months) in the national marketing of snus, 
so that receptivity in other areas may not have had a chance to develop.
This study is an effort to estimate receptivity to snus use in the U.S. locations where the two 
most highly advertised products have been available the longest: Dallas/Fort Worth, Texas 
and Indianapolis, Indiana. Our purpose was to establish benchmarks for the following: rates 
of awareness, trial, progression to regular use, motivations for trial, and reasons for not 
continuing to use snus. We also examined the demographic characteristics of those taking up 
snus, and the associations between snus use, cigarette smoking history and intentions to quit.
 METHODS
 Sample Design
Male smokers and young adults, those most likely to use snus, were oversampled.19, 20 A 
dual-frame, address-based sample was used: a list frame and the U.S. Postal Service 
Delivery Sequence File (DSF). The list frame consisted of addresses and telephone numbers 
of households believed to include a male smoker and/or an individual between the ages of 18 
and 25. For the sample of addresses selected from the DSF file, a phone matching service 
was able to provide phone numbers for 55.6% of the randomly selected households. 
Telephone numbers and addresses obtained for the DSF file were then unduplicated from the 
list sample. The telephone survey was supplemented by a brief mail survey of a sample of 
the DSF addresses for which no phone numbers could be obtained to address potential bias 
due to non-inclusion of such households. The mail survey included only a subset of 
1The rate in all smokers is estimated based on the finding that 75% of all smokers were daily smokers.
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questions (e.g. demographics, smoking status, ever and current use of various forms of 
tobacco). However, all mail respondents were asked if they would be interested in 
completing a follow-up phone survey for which they would be paid $25. All interested mail 
respondents who provided a phone number and reported being a smoker were telephoned 
and administered the entire phone survey. The combined list and DSF samples were 
representative of the population of the two areas. Data were weighted to account for the 
probability of selection and survey non-response, and were then post-stratified to match the 
sample to the age, gender, and smoking status of persons in the two geographic regions 
being sampled. Data were collected between February, 2011 and June, 2012.
 Measures
 Conventional Tobacco Use—Measures of tobacco use assessed ever and current use 
of cigarettes, and conventional smokeless tobacco (CSLT). Current cigarette smoking was 
defined as having smoked 100 cigarettes in one’s lifetime, and currently smoking “some 
days” or “every day.” Current use of CSLT was defined as using “chewing tobacco, dip or 
snuff” at least 20 times, and having used it in the past 30 days.
 Snus Awareness and Use—Because snus is a relatively new product, and has been 
shown to be confused with conventional moist snuff,23 efforts were made to ensure that 
respondents who reported using snus were, indeed, referring to the new LNSLT products. 
Confirmed awareness of snus was measured with the following questions on the phone 
survey only: “New smokeless tobacco products are now available that come in teabag-like 
pouches that are put in the mouth under the lip. They do not involve spitting or chewing. 
They are called snus (rhymes with goose) or snuhss (rhymes with bus). Have you ever heard 
of products like these?“ Those who responded affirmatively were asked which pronunciation 
they favored, and what brand names of snus products they had heard of. If they did not 
mention either Camel or Marlboro Snus, they were asked whether they recognized either of 
those two brand names. Confirmed awareness was defined as having heard of the products 
and either naming a recognized LNSLT product or recognizing the brand Marlboro or Camel 
Snus. To measure trial, those who confirmed awareness were asked, “ Have you ever tried 
any snus products, even one time?” Those who responded affirmatively were asked, “ What 
snus product have you tried?” Respondents who named a recognized LNSLT brand were 
considered snus triers. On the mail survey, trial was measured with a similar question, but 
respondents were simply asked to check the brand of snus they had tried from a list of snus 
brands (Camel, Marlboro, General, Taboka, Other). On both surveys, a former user of snus 
was defined as a respondent who was a trier who reported having used at least 20 pouches of 
snus, but had not used in the past 30 days. A current snus user was defined as a trier, who 
had used at least 20 pouches and reported use in the past 30 days. Some analyses combine 
former and current users, who are referred to as “ever users”.
 Potential Predictors of Snus Use—In the population as a whole, the following 
predictors of snus use were assessed: age, gender, education, racial/ethnic minority status, 
smoking and CSLT status. Separate analyses were carried out for male smokers that 
examined number of cigarettes per day; having tried to quit smoking in the past two years; 
expectations of quitting smoking in the coming year; CSLT status; being a recipient of 
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tobacco promotional mailings; and exposure to up to 3 smoking bans (at home, work, and 
local restaurants).
 Reasons for trying and for giving up snus—Snus triers and former users were 
asked to provide up to three reasons for trial. These open-ended responses were coded into 
categories endorsed by multiple respondents using thematic analysis.24 Five reasons were 
most prevalent : curiosity; could be obtained for free or reduced cost; to use where smoking 
wasn’t permitted; to cut down on or quit smoking cigarettes; and to substitute for CSLT. Two 
coders independently read each comment and decided whether it fit into any of the five 
categories. Disagreements were rare and were resolved by the first author. Respondents were 
given a dichotomous score indicating mention or no mention of each category. A close-
ended strategy was used to assess reason for not continuing to use snus. Snus triers and 
former users were presented with 10 possible reasons for not continuing to use snus and 
asked to rate each as very, somewhat or not important. These ranged from its taste and feel 
to concerns about how others viewed it.
Current snus users who were also smokers were asked to indicate whether they did or did 
not use snus for each of the following reasons: 1) where smoking is not permitted, 2) when 
others prefer they do not smoke, 3) to avoid exposing others to tobacco smoke, 4) to avoid 
smelling like smoke, and 5) to help reduce or 6) to quit smoking.
 Analysis Plan
Cross tabulations and logistic regression analyses examined rates and predictors of snus use 
using IBM SPSS version 20, complex sample procedures. Descriptive statistics were 
calculated to report on reasons for trying and using snus, and reasons for not continuing to 
use snus.
 RESULTS
The response rates for the various data collection modes were as follows: original telephone 
sample – 27.5%; mail sample – 32%; phone follow-up of mail respondents – 54.7%. The 
cooperation rate for the original phone sample (i.e. the proportion of eligible contacted 
households that yielded a completed survey) was 57.3%. Table 1 shows the size and 
characteristics of the phone and mail samples. A corresponding table showing the 
unweighted characteristics of the sample is available online as supplementary material 
(Supplementary table S1). The weighted analyses indicate no significant mode effects on 
snus trial and use.
 Snus awareness and use
As Table 2 shows, more than a quarter of the adult population was aware of the new snus 
products, but only 6% reported trying it at least once; 4.6% were ever users, and less than 
1% of the population reported being a current user. Awareness was highest among smokers 
(59.9%) and lower among former (41.5%) and never smokers (18%) (p<.001). Trial was 
highest among smokers (21.2%) and much lower for former smokers (6.2%) and never 
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smokers (2.4%) (p<.001). Snus trial was higher among male smokers (29.9%) than among 
female smokers (8.5%)(p<.001).
It is apparent that about one-third of the male smokers who tried the new product, went on to 
become ever users (i.e. to use it at least 20 times) and about 14% of those who tried it 
reported being current users (4.2% of all male smokers). Ever use of snus was very rare 
among female smokers (< 1% ). Among male former and never smokers, trial was reported 
by 9.8% and 5%, respectively, and ever use was 3.8% and 3.4% respectively. However, 
current use was below 1% for both current and former male smokers. Among female former 
and never smokers, trial and repeated use was low and current use was virtually absent. 
Because of the very low rate of current use of snus, regression models will yield unstable 
results.25 Therefore, further multivariate analyses of snus use focused on ever users (i.e. 
former and current users).
 Predictors of Snus Awareness and Use
Logistic regression assessed the demographic and tobacco use predictors of awareness and 
use of snus (Table 3). Among the demographic predictors (gender, age group, race/ethnicity 
and education), only education had a significant independent association with snus 
awareness with less educated individuals being more aware of snus. Tobacco use status was 
a significant predictor of awareness; current users of CSLT were almost 6 times as likely to 
be aware of snus as non-users. Current smokers were four times as likely to be aware than 
nonsmokers.
Trial and ever use of snus was significantly more likely in males, younger people, and those 
with less than a college education. White, non-Hispanic respondents were more than twice 
as likely to report trying snus, but race/ethnicity was not significantly related to ever use.. 
Current tobacco use was an important predictor of snus trial; smokers and CSLT users were 
six to eight times as likely to try snus as those not using tobacco in these forms. Current 
CSLT users were more than seven times as likely to become ever users as non-CSLT users, 
but controlling for CSLT status, smoking status was not significantly associated with snus 
use beyond trial.
 Predictors of snus use among male smokers—Oversampling of male smokers 
permitted a closer look at the predictors of snus use in that group. Age was an important 
predictor of snus trial among male smokers, but was not of ever use (Table 4). Neither race/
ethnicity nor education predicted trial, but ever use was significantly more likely among 
white non-Hispanic respondents than among minorities. Respondents who were recipients of 
tobacco promotions were more likely to try snus, but not necessarily more likely to progress 
to ever use. Sixty-one percent of male smokers tried to quit in the past two years. Quit 
attempts were not significantly associated with snus trial in bivariate analyses (67% vs 59%, 
p = .53); but quit attempts were almost universal among those who used snus 20 or more 
times (90% vs 58%, p =.01). These relationships held up in the multivariate analysis as well. 
However, compared to those who expected to quit smoking in the coming year, smokers who 
believed that they would still be smoking in 12 months were significantly more likely to 
both try and to continue using snus. Male smokers smoked an average of 16.9 cigarettes per 
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day. Smoking rate was slightly lower among those who tried snus versus those who did not 
( 14.7 vs 18.1, p = .11), as well as among those who used snus at least 20 times versus those 
who did not (16.1 vs 17.0). Multivariate analysis demonstrated that number of cigarettes 
smoked per day was not independently associated with snus trial or ever use. Exposure to 
smoke-free environments was unrelated to snus use. Smokers who also used CSLT were 
much more likely to try snus and to progress to ever use.
 Smokers’ reasons for trying and then giving up snus
Of ever triers, most (54.4%) used snus only once or twice. Among smokers who did not 
become current snus users, the most frequently cited reasons for trying snus were the 
following: curiosity (41.3%; 95% CI: 23.5, 61.7); to take advantage of a free sample or a 
coupon (30.3%; 95% CI: 14.2, 53.4); to see whether it would help with quitting smoking or 
cutting down on cigarettes smoked (25.5%; 95% CI: 11.7, 47.0); and to use where smoking 
was not permitted (20.0%; 95% CI: 8.7, 39.6). There were several gender differences in the 
reasons for trying snus: Women were significantly more likely than men to report wanting to 
use snus in smokefree areas (49.7% vs. 12.3%; p = .04) and significantly less likely than 
men to report wanting to use it to reduce or quit smoking (3.1% vs. 22.4%; p = .03).
When asked to rate 10 possible reasons for not continuing to use snus, the four most often 
endorsed as “very important” were: liking another form of tobacco better (75.1%; 95% CI: 
54.0, 88.6), not liking the way it felt in the mouth (34.6%; 95% CI: 19.0, 54.4), disliking the 
taste (26.8%; 95% CI: 13.5, 46.3), and feeling sick when using it (21.5%; 95% CI: 10.6, 
38.6). Men were less likely than women to fault the taste and mouth feel of snus, and women 
were significantly more likely than men to report that they thought it made them look bad to 
use snus. Detailed tables showing levels of endorsements for all reasons for trying and 
giving up snus are available online in Supplementary tables S2 and S3.
 Reasons for use among current snus users
Of smokers who reported using snus in the past month (n = 29), only 3.9% (95% CI: 1.5, 
9.6) indicated that they were using snus to try to quit smoking, but 98% (95% CI: 95.1, 99.3) 
said they were using snus to try to cut down on the number of cigarettes they smoked; 83% 
(95% CI: 44.7, 96.8) indicated that they wanted to avoid exposing others to second hand 
smoke; 75.7% (95% CI: 47.1, 91.6) wanted to avoid smelling like tobacco smoke. Only 28% 
(95% CI: 11.7, 53.6) said they used snus when they were in no-smoking areas, and fewer 
still (4.3%; 95% CI: 1.8, 9.8) reported using it when others preferred that they not smoke. 
Almost all of the current snus users (96.7%; 95% CI: 87.8, 99.2) believed it was very or 
somewhat likely that they would be using snus in 12 months. Most of those who were 
current smokers expected to be smoking in 12 months (83.9; 95%CI: 48.3, 96.7%). Virtually 
all who were also current CSLT users expected to still be using that form of tobacco in 12 
months.
 DISCUSSION
This study provides realistic estimates of the awareness, trial and continuing use of snus 
given availability and marketing strategies in the U.S. as of 2012. Our findings indicate that 
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although most smokers (60%) are aware of snus, and 21% try it at least once, (almost twice 
the rate reported by McMillan et al.) 21 very few go on to use it regularly. Past month use is 
estimated at about 1% of all men and 4.2% of male smokers, less than half of what can be 
estimated from King et al. 22. Past month use is virtually absent among female smokers. In 
addition we confirm to earlier findings that snus use is primarily a young male smoker 
phenomenon and that trial is a significant function of receiving tobacco promotions. 19, 20 
What has been learned for the first time in this study is that experience with conventional 
smokeless tobacco (CSLT) is one of the strongest predictors of both snus trial and continued 
use. Although our sample included relatively few current users of CSLT (n=155), among 
male CSLT users 51% had tried snus and 29% were ever users; among male smokers not 
also using CSLT, only 25% tried snus and only 4.6% were ever users.
There are study limitations that must be considered when interpreting the findings. The 
sampling strategy resulted in rather large design effects that tend to increase the confidence 
intervals around some estimates, especially among subgroups that were not oversampled. 
Also, the low prevalence of regular snus use leads us to interpret findings based on that small 
group cautiously. Nevertheless, this study has many methodological advantages over 
previous work. It used a population-based sample in two geographic areas that served as 
early test markets for the major snus brands, so we can be confident that the products were 
available for a sufficient period of time to allow for meaningful estimates of population 
awareness, trial, and progression to regular use. The survey required that respondents 
confirm reports of snus awareness and use by providing brand names; therefore estimates are 
unlikely to be inflated by confusion with conventional pouched smokeless tobacco. 23 Male 
smokers, the primary target of snus marketing, were oversampled insuring a sufficient 
sample for relatively precise estimates of trial and continuing use. The fact that we were 
unable with available resources to oversample recent former smokers is a limitation of the 
current design. Consequently, although we saw that snus use is associated with quit attempts 
among current smokers, we did not have a sufficient number of cases to examine the extent 
to which snus use is associated quitting smoking.
One concern that has been raised about snus is that it could lure former smokers back to 
tobacco use or even attract never smokers. Indeed, among the male respondents, almost 10% 
of former smokers tried snus, and almost 4% persist to use it more than 20 times. However, 
under 1% became current users. A similar pattern of low levels of experimentation (5%) and 
ever use (3.4%) applies to male never-smokers. If current and former CSLT users are 
removed from the male analyses, the rate of trial by former male smokers drops from 10% to 
4% and ever use from 3.4% to less than 1%. Snus trial and use among male never smokers 
who never used CSLT is even lower, and for both former and never smokers who never used 
CSLT, current use of snus is nonexistent.
Analysis of smokers who tried snus but did not continue using the product provides some 
insight into what sparked their initial interest. The most frequent reasons given were 
curiosity and the ability to obtain the product either for free or at a low price. Less often, 
these experimenters said they wanted to see if it might be useful in quitting smoking or at 
least cutting down (these two reasons could not be untangled in coding). Although only 2 
people mentioned that snus was probably less harmful to health than smoking, many who 
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wanted to use it to cut down implied, in the words of one respondent, that they “wanted to 
give (their) lungs a break” from the smoke. Once they tried the product, however, they found 
it less desirable than their primary form of tobacco use, i.e. cigarettes. Most endorsed the 
item, “prefer another form of tobacco” as an important reason for quitting snus; also noted 
were a dislike of the taste, mouth-feel, and the fact that it made them feel sick.
It is interesting that among the few current snus users who are also smokers, the primary 
reason for using is not to get them through periods where they are not able to smoke, as has 
been feared, but rather “to cut down on smoking.” Like those who don’t continue with the 
product, they are trying to smoke less.
In conclusion, given the current snus design and marketing featuring strong health warnings, 
this study suggests that both the hopes and the fears surrounding this new type of tobacco 
product are unlikely to materialize in the U.S. Although a good proportion of the smokers, 
who are the target of marketing, have been willing to try the product at low or no cost, unless 
they also have some experience using CSLT, they are very unlikely to progress to regular 
use. They enjoy cigarettes too much and find the experience of putting tobacco pouches in 
their mouth quite unpleasant. Thus to date, the major public health benefit that has been 
hoped for, the reduction in smoking in favor of smokeless use, is unlikely to occur in the U. 
S. as it has among Swedish men. Concomitantly, there seems little reason for concern that 
substantial numbers of former or never-smokers, especially those without CSLT experience, 
will use snus regularly. The few individuals who do progress to regular snus use, however, 
do appear to be using it as an adjunct to their conventional tobacco use (cigarettes and 
CSLT). Therefore, the impact of this additional product on health bears monitoring.
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Refer to Web version on PubMed Central for supplementary material.
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Table 3
Adjusted Odds Ratios for Snus Awareness and Receptivity
Aware of Snusa (n = 3,434) Tried Snus (n = 5,077) Ever Used Snusb (n = 5,077)
Dependent Variable Adjusted OR (95% CI) Adjusted OR (95% CI) Adjusted OR (95% CI)
Gender
 Male 2.18 (0.97–4.89) 6.88* (3.05–15.53) 12.27* (2.78–54.17)
 Female 1.00 1.00 1.00
Age Group (3 Level)
 18–30 0.84 (0.30–2.38) 11.01* (4.38–27.69) 7.21* (1.49–34.81)
 31–49 1.02 (0.34–3.08) 4.34* (2.06–9.14) 2.93 (0.92–9.31)
 50–65 1.00 1.00 1.00
Race/Ethnicity
 White/Non-Hispanic 1.41 (0.55–3.65) 2.37* (1.05–5.36) 4.70 (0.99–22.25)
 Minority 1.00 1.00 1.00
Education (2 Level)
 Less than BA 3.27* (1.35–7.92) 2.67* (1.20–5.97) 4.79* (1.31–17.53)
 BA or more 1.00 1.00 1.00
Smoking Status
 Current Smoker 4.01* (1.84–8.71) 7.99* (4.02–15.87) 1.87 (0.60–5.88)
 Former/Non-smoker 1.00 1.00 1.00
CSLT Status
 Current User 5.70* (1.77–18.40) 6.68* (3.02–14.80) 7.24* (2.02–25.99)
 Not a Current User 1.00 1.00 1.00
a
Includes values for phone respondents only;
bCombines former users and current users.
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Table 4
Adjusted Odds Ratios for Snus Receptivity among Male Smokers
Tried Snusa (n = 945) Ever Usedb (n = 945)
Dependent Variable Adjusted OR (95% CI) Adjusted OR (95% CI)
Age Group
 18–30 71.38* (10.80–471.83) 1.46 (0.14–15.19)
 31–49 2.47 (0.61–9.94) 2.08 (0.30–14.49)
 50–65 1.00 1.00
Race/Ethnicity
 White/Non-Hispanic 1.50 (0.24–9.49) 7.69* (1.14–51.86)
 Minority 1.00 1.00
Education
 BA or more 0.36 (0.12–1.11) 0.49 (0.08–2.95)
 Less than BA 1.00 1.00
Tried to quit in past 2 yrs
 Yes 0.80 (0.19–3.35) 14.63* (2.47–86.81)
 No 1.00 1.00
Likely to be smoking in 12 months
 Yes 4.75* (1.69–13.35) 6.99* (1.10–44.62)
 No 1.00 1.00
Received tobacco promotion in mail in past 12 months
 Yes 7.62* (2.12–27.44) 5.68 (0.55–58.78)
 No 1.00 1.00
SLT Status
 Current User 13.69* (3.23–57.96) 70.60* (13.71–363.49)
 Not a Current User 1.00 1.00
Number of cigarettes smoked per day 0.98 (0.94–1.03) 1.01 (0.95–1.07)
Number of smoke-free environments 0.93 (0.51–1.69) 0.66 (0.27–1.66)
Note:
a
Includes those who used snus 1 or more times.
bCombines former and current users: Those who used snus at least 20 times.
*
P < .05
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